ArticleJournal of translational medicine2025
Spatial transcriptomics reveal high T cell and monocyte status as predictive and prognostic markers in pancreatic cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundIn the present study, we intended to discover predictive or prognostic factors of pancreatic ductal adenocarcinoma (PDAC). We intended to investigate the differences between PDAC cases that are treated with upfront surgery (UFS) and surgery after neoadjuvant FOLFIRINOX chemotherapy (NAT), and cases with good and poor responses to NAT, using digital spatial profiling (DSP) and immunohistochemical (IHC) analysis.
methodsForty-eight PDAC cases that were surgically resected with or without NAT were included. A tissue microarray was constructed for DSP and IHC. Pathological tumor regression to NAT was graded based on the College of American Pathologists (CAP) system.
resultsBetween the UFS and NAT groups, there were no significant differentially expressed genes in all cell types. In the NAT group, MFAP4 and EGR3 were upregulated in CAP 2 in pan CK- and CD45-negative cells. Gene set enrichment analysis of CD45-positive cells showed that genes related to B or T cell-associated pathways were enriched in CAP 2, which correlated with the IHC; higher CD3-, CD4-, and CD8-positive cell densities in CAP 2. Multivariate analysis revealed age, high monocyte infiltration, and high CD68-positive cell infiltration as independent prognostic factors for overall survival.
conclusionsIncreased expression of MFAP4 and EGR3 as well as high CD3-, CD4-, and CD8-positive cell infiltration may be predictive markers of the NAT response in PDAC. Additionally, high monocyte infiltration and high CD68-positive cell infiltration could serve as prognostic markers for PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.